Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 53 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

21%

11 trials in Phase 3/4

Results Transparency

0%

0 of 22 completed trials have results

Key Signals

14 recruiting

Enrollment Performance

Analytics

Phase 1
25(47.2%)
Phase 2
17(32.1%)
Phase 3
11(20.8%)
53Total
Phase 1(25)
Phase 2(17)
Phase 3(11)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (53)

Showing 20 of 53 trials
NCT06246175Phase 1Completed

A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy Subjects

Role: lead

NCT06762600Phase 1Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects

Role: lead

NCT07559136Phase 1Not Yet Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity

Role: lead

NCT07551492Phase 3Not Yet Recruiting

A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease

Role: lead

NCT07540754Phase 1Not Yet Recruiting

A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function

Role: lead

NCT07318103Phase 2Recruiting

Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention

Role: lead

NCT07185776Phase 2Active Not Recruiting

A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

Role: lead

NCT07308392Phase 2Recruiting

Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis

Role: lead

NCT07285902Phase 3Active Not Recruiting

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

Role: lead

NCT07297797Phase 2Recruiting

Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension

Role: lead

NCT06994650Phase 3Recruiting

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy

Role: lead

NCT07060456Phase 3Recruiting

Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin

Role: lead

NCT06391710Phase 2Active Not Recruiting

HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction

Role: lead

NCT07233070Phase 2Recruiting

HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke.

Role: lead

NCT06554184Phase 3Completed

HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

Role: lead

NCT06934408Phase 1Recruiting

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection

Role: lead

NCT07150962Phase 1Recruiting

Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects

Role: lead

NCT06506994Phase 1Completed

A Study of HRS-9057 in Patients With Heart Failure and Volume Overload

Role: lead

NCT07195604Phase 1Recruiting

A Single Ascending Dose of HRS-2162 in Healthy Subjects

Role: lead

NCT06425341Phase 2Recruiting

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

Role: lead